Foreign expansion of hypertension/hyperlipidemia complexes

Domestic hypertension and hyperlipidemia complexes have aggressively knocked on the door of foreign markets. They have either been directly conducted on foreign clinical trials or been jointly developed with global big pharmaceuticals.

On the 9^th, Boryung Pharm announced approval for a Phase 1 clinical trial of its self-developed fimasartan/rosuvastatin complex in the U.S. Fimasarrtan is a su...